Multivariate analysis of the BPM in the training and the validation sets of patients with DLBCL
. | Overall survival . | Event-free survival . | ||||
---|---|---|---|---|---|---|
Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
Training set | ||||||
BPM score 2-3 | 4.3 | 2.1-9.0 | .0001 | 3.6 | 1.9-6.6 | < .0001 |
IPI score 3-5 | 2.7 | 1.3-5.3 | .0052 | 1.1-3.8 | .018 | |
Validation set | ||||||
BPM score 2-3 | 5.2 | 2.2-12.3 | .0002 | 3.5 | 1.7-7.4 | .0008 |
IPI score 3-5 | 3.5 | 1.6-7.9 | .0026 | 2.6 | 1.2-5.4 | .011 |
. | Overall survival . | Event-free survival . | ||||
---|---|---|---|---|---|---|
Hazard ratio . | 95% CI . | P . | Hazard ratio . | 95% CI . | P . | |
Training set | ||||||
BPM score 2-3 | 4.3 | 2.1-9.0 | .0001 | 3.6 | 1.9-6.6 | < .0001 |
IPI score 3-5 | 2.7 | 1.3-5.3 | .0052 | 1.1-3.8 | .018 | |
Validation set | ||||||
BPM score 2-3 | 5.2 | 2.2-12.3 | .0002 | 3.5 | 1.7-7.4 | .0008 |
IPI score 3-5 | 3.5 | 1.6-7.9 | .0026 | 2.6 | 1.2-5.4 | .011 |
BPM indicates biologic prognostic model; DLBCL, diffuse large B-cell lymphoma; CI, confidence interval; and IPI, International Prognostic Index.